0001209191-23-006324.txt : 20230202
0001209191-23-006324.hdr.sgml : 20230202
20230202175647
ACCESSION NUMBER: 0001209191-23-006324
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230201
FILED AS OF DATE: 20230202
DATE AS OF CHANGE: 20230202
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gros David-Alexandre C
CENTRAL INDEX KEY: 0001644489
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36620
FILM NUMBER: 23582617
MAIL ADDRESS:
STREET 1: 220 MARLBOROUGH STREET
STREET 2: #6
CITY: BOSTON
STATE: MA
ZIP: 02116
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Eledon Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001404281
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 19900 MACARTHUR BLVD.
STREET 2: SUITE 550
CITY: IRVINE
STATE: CA
ZIP: 92612
BUSINESS PHONE: 949-238-8090
MAIL ADDRESS:
STREET 1: 19900 MACARTHUR BLVD.
STREET 2: SUITE 550
CITY: IRVINE
STATE: CA
ZIP: 92612
FORMER COMPANY:
FORMER CONFORMED NAME: Novus Therapeutics, Inc.
DATE OF NAME CHANGE: 20170511
FORMER COMPANY:
FORMER CONFORMED NAME: Tokai Pharmaceuticals Inc
DATE OF NAME CHANGE: 20070622
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-02-01
0
0001404281
Eledon Pharmaceuticals, Inc.
ELDN
0001644489
Gros David-Alexandre C
C/O ELEDON PHARMACEUTICALS, INC.
19900 MACARTHUR BLVD STE. 550
IRVINE
CA
92612
1
1
0
0
Chief Executive Officer
Stock Option (right to buy)
3.08
2023-02-01
4
A
0
300000
0.00
A
2033-02-01
Common Stock
300000
300000
D
Stock Option (right to buy)
3.97
2023-02-01
4
A
0
153600
0.00
A
2032-02-01
Common Stock
153600
153600
D
This option represents a right to purchase up to 300,000 shares of Common Stock, which options vests with respect to 75,000 shares on February 1, 2024, and then with respect to 6.25% of the underlying shares quarterly over the three year period ending February 1, 2027.
This transaction represents the attainment of the performance conditions applicable to an option award subject to both performance-based and time-based vesting criteria granted to the reporting person on February 1, 2022. The option satisfied the performance criteria with respect to 153,600 shares of underlying Common Stock and these credited shares will satisfy the time-based vesting criteria with respect to 38,400 shares of Common Stock on February 1, 2023, and then with respect to 1/48th of the credited shares monthly over the three-year period ending February 1, 2026.
/s/ David-Alexandre C. Gros
2023-02-02